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TNBC describes the 10–20% of tumors that are estrogen recep-tor (ER)-, progesterone receptor (PgR)- and HER2-negative. However, assuming that TNBC is a single entity is a fallacy masking considerable histological and biological heterogeneity among tumors, which must be understood to optimize therapy selection. Outcome for a patient with recurrent and/or advanced 
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Germline mutations in BRCA1/2 predispose individuals to breast cancer (termed germline-mutated BRCA1/2 breast can-
cer, gBRCA-BC) by impairing homologous recombination (HR) and causing genomic instability. HR also repairs DNA lesions 
caused by platinum agents and PARP inhibitors. Triple-negative breast cancers (TNBCs) harbor subpopulations with BRCA1/2 
mutations, hypothesized to be especially platinum-sensitive. Cancers in putative ‘BRCAness’ subgroups—tumors with BRCA1 
methylation; low levels of BRCA1 mRNA (BRCA1 mRNA-low); or mutational signatures for HR deficiency and those with basal 
phenotypes—may also be sensitive to platinum. We assessed the efficacy of carboplatin and another mechanistically dis-
tinct therapy, docetaxel, in a phase 3 trial in subjects with unselected advanced TNBC. A prespecified protocol enabled bio-
marker–treatment interaction analyses in gBRCA-BC and BRCAness subgroups. The primary endpoint was objective response 
rate (ORR). In the unselected population (376 subjects; 188 carboplatin, 188 docetaxel), carboplatin was not more active than 
docetaxel (ORR, 31.4% versus 34.0%, respectively; P =  0.66). In contrast, in subjects with gBRCA-BC, carboplatin had dou-
ble the ORR of docetaxel (68% versus 33%, respectively; biomarker, treatment interaction  P =  0.01). Such benefit was not 
observed for subjects with BRCA1 methylation, BRCA1 mRNA-low tumors or a high score in a Myriad HRD assay. Significant 
interaction between treatment and the basal-like subtype was driven by high docetaxel response in the nonbasal subgroup. We 
conclude that patients with advanced TNBC benefit from characterization of BRCA1/2 mutations, but not BRCA1 methylation or 
Myriad HRD analyses, to inform choices on platinum-based chemotherapy. Additionally, gene expression analysis of basal-like 
cancers may also influence treatment selection.
TNBC is especially poor1. Chemotherapy is the only approved 
systemic therapy and, although considered biologically unselec-
tive, can have distinct mechanisms of action that target specific 
biological mechanisms that are aberrant in cancer. When accom-
panied by mechanism-relevant biomarkers, the use of a specific 
chemotherapeutic in defined populations might be considered a 
‘targeted’ therapy.
Although genomic classifiers suggest that the majority of TNBCs 
are of the basal-like intrinsic subtype2,3, recent analyses suggest that 
TNBC can be subclassified4–6. An immunohistochemical (IHC) 
approximation of the basal-like intrinsic subtype has been termed 
‘core basal’7. A common feature of sporadic basal TNBC is genomic 
instability with mutational and rearrangement signatures indicative 
of abnormalities in DNA repair and replication stress that overlap 
BRCA1/2-mutation-associated signatures8. Abnormalities also exist 
in BRCA1 mRNA expression that are largely driven through meth-
ylation of the BRCA1 promoter9,10, as observed in ovarian cancer11,12. 
This and the overlap in mutational signatures8 suggest functional 
deficiency of genes with known roles in DNA repair by HR as a 
shared characteristic between BRCA1 hereditary breast cancers and 
a substantial, but incompletely defined, subgroup of TNBC. BRCA1 
and BRCA2 proteins have important roles in DNA replication fork 
stabilization and HR13 and are components of the Fanconi anemia 
protein network14,15. The hallmark of deficiency in this network is 
sensitivity to DNA crosslinks induced by platinums and mitomy-
cin C16,17. Historically, platinum chemotherapies have only shown 
modest activity in advanced breast cancer except for chemotherapy-
naive disease18,19.
No trial has directly studied responses to platinum therapy in 
comparison to standard of care in advanced unselected TNBC, 
its majority basal subtype or subgroups of TNBC with features of 
aberrant BRCA1/2-associated function or ‘BRCAness’20. The TNT 
Trial was designed to compare the activity of the standard of care 
microtubule-disrupting agent docetaxel with the DNA-crosslinking 
agent carboplatin. We hypothesized that carboplatin would have 
greater activity than docetaxel in subgroups deficient in DNA dam-
age response. Considering that strong mechanistic evidence exists 
for the efficacy of carboplatin and cisplatin in cells with BRCA1/2 
mutations, accrual of patients known to have these germline muta-
tions was allowed irrespective of ER, PgR and HER2 status. We pre-
specified analyses of (i) BRCA1/2 germline mutation carriers and of 
members of putative BRCAness21 TNBC subgroups with (ii) DNA 
methylation at the BRCA1 promoter and/or low  BRCA1 mRNA 
expression and the basal-like phenotype as defined by (iii) gene or 
(iv) protein expression.
Results
Between 25 April 2008 and 18 March 2014, 376 subjects (188 allo-
cated to carboplatin and 188 to docetaxel) entered the trial, and 
all subjects were included in the analysis of the primary endpoint 
(Fig. 1); the trial population largely comprised patients with TNBC 
and no known BRCA1/2 mutation (338 of 376) and with baseline 
characteristics typical of patients with relapse of TNBC follow-
ing first-line therapy (Supplementary Tables 2 and 3). There were 
43 subjects with germline BRCA1/2 mutation (31 BRCA1 and 12 
BRCA2; Supplementary Table  2). Of the 31 carriers of a BRCA1 
mutation, 4 had ER-positive disease, and 7 of the 12 carriers of a 
BRCA2 mutation had ER-positive disease. Compliance with allo-
cated treatment was good; disease progression and toxicity were 
the principal reasons for early discontinuation. The median relative 
dose intensity was 94.0% (interquartile range (IQR), 84.2–99.8%) 
for carboplatin and 94.8% (IQR, 84.8–100.0%) for docetaxel.
Overall results. There was no evidence of a difference between 
the ORR to carboplatin and to docetaxel in the overall popula-
tion (ORR, 31.4% (59 of 188 carboplatin-treated subjects) versus 
34.0% (64 of 188 docetaxel-treated subjects); absolute difference 
(calculated as carboplatin ORR – docetaxel ORR), − 2.6%; 95% CI, 
− 12.1 to 6.9; P = 0.66; Fig. 2a). Following central review of locally
classified responses, response rates were determined to be 25.5%
(48 of 188 subjects) for carboplatin versus 29.3% (55 of 188 subjects) 
for docetaxel (absolute difference, − 3.8%; 95% CI: − 12.8 to 5.2;
P = 0.49), consistent with findings from the main analysis. Similarly, 
no difference was observed based on responses to crossover treat-
ment with the alternative drug (crossover treatment; Supplementary 
Fig. 1a) or when analysis was limited to those centrally confirmed as 
having TNBC tumors (Supplementary Note).
Of the 376 subjects in the trial, 372 (98.9%) had progression-free 
survival (PFS) events reported. Median PFS in subjects allocated 
carboplatin was 3.1 months (95% CI, 2.4–4.2), and median PFS was 
4.4 months (95% CI, 4.1–5.1) for those allocated docetaxel. No dif-
ference in restricted mean PFS was found (difference in restricted 
mean PFS (calculated as carboplatin restricted mean PFS – docetaxel 
restricted mean PFS), − 0.30 months; P = 0.40; Fig. 3a).
There were 347 subjects who were reported to have died. Median 
overall survival (OS) was 12.8 months (95% CI, 10.6–15.3) and 
12.0 months (95% CI, 10.2–13.0) for those allocated carboplatin or 
docetaxel, respectively. Consistent with the PFS result, no evidence 
of a difference in OS was found between treatment groups (differ-
ence in OS (calculated as carboplatin restricted mean OS – docetaxel 
restricted mean OS), − 0.03 months; P = 0.96; Supplementary Fig. 2a).
BRCA subgroup analyses. Analyses of BRCA1/2 mutation sub-
groups, which were prespecified in study protocols, were con-
ducted at the time of the main analysis. Subjects with a deleterious 
BRCA1/2 germline mutation had a significantly better response to 
carboplatin than to docetaxel (ORR, 68% (17 of 25 carboplatin-
treated subjects) versus 33.3% (6 of 18 docetaxel-treated subjects); 
absolute difference, 34.7%; P = 0.03), and there was no evidence of 
differential treatment activity in subjects with no germline mutation 
(ORR, 28.1% (36 of 128 carboplatin-treated subjects) versus 34.5% 
(50 of 145 docetaxel-treated subjects); absolute difference, − 6.4%; 
P = 0.30), resulting in a statistically significant interaction between 
therapy and BRCA1/2 mutation status (P = 0.01; Fig. 2b). This result 
remained significant (P = 0.01) after adjustment for known prog-
nostic factors (Supplementary Note). PFS was also longer in subjects 
with a BRCA1/2 germline mutation who were treated with carbo-
platin (median PFS, 6.8 months (carboplatin) versus 4.4 months 
(docetaxel); difference in restricted mean PFS, 2.6 months; interac-
tion P = 0.002; Fig. 3b), but no difference was found between groups 
in OS (Supplementary Fig. 2b), with interpretation confounded by 
the preplanned crossover at progression (Supplementary Fig. 1b). 
Considering the small number of BRCA2 versus BRCA1 germline 
mutation carriers who were  randomized, comparative analyses of 
interaction between treatment effect and each mutated gene were 
neither significant nor meaningful; this also held true for assess-
ment of treatment interaction with ER status, as there was a very 
small number of ER-positive tumors.
Subjects with tumor tissue available for sequencing and a BRCA1/2 
mutation detected in their tumor sample (see Supplementary Table 4 
for overlap of mutation detected in tumor with germline BRCA1/2 
mutation status) appeared to have a better response to carboplatin 
than to docetaxel (ORR, 66.7% (12 of 18 carboplatin-treated sub-
jects) versus 35.7% (5 of 14 subjects); absolute difference, 31.0%; 
P = 0.15); however, docetaxel had a more positive treatment effect 
in subjects with wild-type BRCA1/2 in their tumor sample (ORR, 
25.6% (23 of 90 carboplatin-treated subjects) versus 35.6% (32 of 90 
docetaxel-treated subjects); absolute difference, − 10.0%; P = 0.20). 
Given the very small number of subjects with tumor mutation data, 
neither of these subgroup analyses attained statistical significance; 
however, considering that the effects were in opposite directions, 
the interaction between treatment effect and BRCA1/2 status in 
tumor was significant (P = 0.03; Fig.  2c). This, however, did not 
hold for PFS or OS (P = 0.12 and P = 0.70, respectively; Fig. 3c and 
Supplementary Fig.  2c). Eight subjects had a germline wild-type 
BRCA genotype but a BRCA mutation in their tumor, which was 
classed as a somatic mutation (Supplementary Table  4); two of 
four carboplatin-treated subjects with these mutations responded 
to therapy, as did two of four docetaxel-treated subjects, but small 
numbers of subjects limit a conclusive interpretation of these data.
Counter to our prespecified hypothesis, subjects with BRCA1 
methylation did not have a better response to carboplatin than to 
docetaxel (ORR, 21.4% (3 of 14 carboplatin-treated subjects) ver-
sus 42.1% (8 of 19 docetaxel-treated subjects); absolute difference, 
− 20.7%; P = 0.28) with no evidence of an interaction observed
(P = 0.35; Figs. 2d and 3d and Supplementary Fig. 2d); we arrived
at similar conclusions when subjects with germline BRCA1/2 muta-
tions were excluded.
Concordant with BRCA1 methylation status, tumors we defined 
as BRCA1 mRNA-low, which methylation was partially associ-
ated with (Supplementary Fig. 3 and Supplementary Table 5), did 
not have a better response to carboplatin than to docetaxel (ORR, 
28.6% (4 of 14 carboplatin-treated subjects) versus 64.7% (11 of 17 
docetaxel-treated subjects); absolute difference, − 36.1%; P = 0.07), 
and evidence of an interaction was lacking (P = 0.07; Figs.  2e 
and 3e and Supplementary Fig. 2e). Again, conclusions were not dif-
ferent when subjects with germline BRCA mutations were excluded. 
Furthermore, exploratory analyses examining any relationship 
between high response to carboplatin and the cut-point for BRCA1 
methylation or BRCA1 mRNA-low did not reveal any notable signal 
that supported our a priori hypotheses that these factors would be 
associated with a better response to carboplatin than to a taxane 
(data not presented).
Homologous Recombination Deficiency subgroup analyses. 
In the initial trial design and first protocol, we hypothesized that 
changes in the genome landscape, which may arise as a consequence 
of defects in HR, could be an indicator of platinum salt sensitivity 
and should be examined for interaction with treatment effect in both 
treatment arms. A number of these assays have been reported8,22–25. 
Here we show the result using the combined Myriad HRD assay26 
performed on treatment-naive primary tissue. We found that the 
great majority of subjects with either germline BRCA1/2 muta-
tion or BRCA1 methylation have a high dichotomized ‘HRD Score’ 
(Supplementary Fig.  4a,b), but subjects with a high HRD Score, 
unlike carriers of a germline BRCA1/2 mutation, did not have a bet-
ter response to carboplatin than to docetaxel (ORR, 38.2% (13 of 
34 carboplatin-treated subjects) versus 40.4% (19 of 47 docetaxel-
treated subjects); absolute difference − 2.2%; P = 1.0), with no evi-
dence of an interaction observed (P = 0.75; Fig. 4a). Similar results 
were found when ‘HR Deficient’ subjects, a definition that grouped 
all subjects with a BRCA1/2 mutation and subjects with wild-type 
BRCA1/2 with a high HRD score, were examined (Fig. 4b). In addi-
tion, no evidence of treatment-specific predictive effects on PFS 
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Fig. 1 | Diagram of study. Flowchart for allocation of participants enrolled in the trial into treatment groups
was found using either HRD definition (Supplementary Fig. 5a,b). 
Subjects with a high HRD score had a greater response to both che-
motherapy agents than those with low scores, but this was not sta-
tistically significant.
Basal subgroup analyses. Given the association between germline 
BRCA1 mutation and the development of basal-like breast cancers, 
we sought to formally test the premise that all basal-like cancers 
and BRCA1-mutated tumors share a loss-of-function phenotype 
of BRCA1 through analyzing interaction between basal-like status 
and platinum treatment in this broader basal-like TNBC group. We 
found no evidence that Prosigna–PAM50 basal tumors had a better 
response to carboplatin compared to docetaxel (ORR, 32.5% (27 of 
83 carboplatin-treated subjects) versus 31.0% (27 of 87 docetaxel-
treated subjects); absolute difference, 1.5%; P = 0.87). However, 
in patients with non-basal-like tumors, response to docetaxel 
was significantly better than to carboplatin (ORR, 72.2% (13 of 
18 docetaxel-treated subjects) versus 16.7% (3 of 18 carboplatin-
treated subjects); absolute difference, − 55.5%; P = 0.002), leading to 
a significant interaction test (P = 0.003; Fig. 5a) and a similar trend 
in crossover treatment response (Supplementary Fig. 6). The inter-
action between treatment and PAM50 subgroups remained sig-
nificant after adjusting for g-BRCA-BC status in the multivariable 
logistic regression model (P = 0.002; Supplementary Table  6) and 
when other known prognostic factors were subsequently included 
in the model. The interaction was also significant for PFS (P = 0.04; 
Fig. 6a) but not OS (P = 0.17; (Supplementary Fig. 7a).
There was no evidence that ‘core basal’ tumors defined by IHC 
analysis had improved response to carboplatin compared with 
docetaxel (ORR, 34.3% (23 of 67 carboplatin-treated subjects) 
versus 29.2% (19 of 65 docetaxel-treated subjects); absolute dif-
ference, 5.1%; P = 0.58). Although there was a higher response 
rate to docetaxel compared with carboplatin in subjects with 
tumors that were negative for expression of ER, PgR, HER2, EGFR 
and Ck5/6 and were nonbasal by IHC (ORR, 41.9% (13 of 31 
docetaxel-treated subjects) versus 19.2% (5 of 26 carboplatin-
treated subjects); absolute difference, − 22.7%; P = 0·09), the 
difference did not reach statistical significance, and the inter-
action test was nonsignificant (P = 0.06; Figs.  5b and 6b and 
Supplementary Fig. 7b).
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Fig. 2 | Response rates documented in the overall population and within BRCA subgroups. a, The absolute difference in the percentage of subjects  
who responded to treatment (carboplatin responders (%) – docetaxel responders (%)) between treatment groups within the overall patient population. 
ITT, intention to treat. b–e, The absolute differences in the percentage of subjects who responded to treatment between treatment groups with subjects 
stratified according to germline BRCA1/2 mutation status (b), tumor BRCA1/2 mutation status (c), BRCA1 methylation status (d) and BRCA1 mRNA-low 
status (e). P values for absolute differences were calculated using a two-sided Fisher’s exact test. P values for the interaction tests are based on the Wald 
statistic from a logistic regression model of response, with terms for biomarker status, treatment group and interaction. The number of subjects who 
responded to treatment out of all subjects in the group is shown on each bar. Axes scales show the percentage of subjects with a response.
Safety. Both carboplatin and docetaxel demonstrated toxicity con-
sistent with their known safety profiles, and grade 3 and 4 adverse 
events (AEs) occurred as anticipated for these well-known chemo-
therapy drugs (Supplementary Tables  7 and 8). There were more 
grade 3 and 4 AEs following treatment with docetaxel than with car-
boplatin. Throughout the trial, 276 serious adverse events (SAEs) 
were reported (102 and 174 in carboplatin- and docetaxel-treated 
subjects, respectively). The spectrum of SAEs was as anticipated. 
Two SAEs were considered to be suspected unexpected serious 
adverse reactions (1 in each treatment group); these were (i) nau-
sea, vomiting and headaches and (ii) low magnesium. One death 
was considered possibly related to carboplatin treatment; this 
subject died from pulmonary embolism. As a haploinsuffiency or 
dominant-negative effect of heterozygous mutation might affect 
toxicity from HR-targeting therapies, such as platinum, in carriers 
of a BRCA mutation, we sought evidence of excess hematological 
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Fig. 3 | PFS in the entire population and in subgroups stratified according to BRCA status. a, PFS for the overall ITT population of subjects treated with 
carboplatin or docetaxel. The difference in restricted mean and 95% CI are shown on the figure. b–e, PFS for treatment groups with subjects stratified 
according to germline BRCA1/2 mutation status (b), tumor BRCA1/2 mutation status (c), BRCA1 methylation status (d) and BRCA1 mRNA-low status (e). 
The difference in restricted means with 95% CIs for stratified groups are shown on the figures. A negative mean indicates a better response to docetaxel, 
and a positive mean indicates a better response to carboplatin. P values were calculated using a two-sided Student’s t-test comparing the restricted mean 
PFS between treatments (within biomarker groups as indicated). C, carboplatin; D, docetaxel. n at risk (events) shows the number of subjects who remain 
in the analysis set at a given time point and the number of PFS events reported between time points.
toxicity as a signal but found none (Supplementary Table  9). 
Although there was a small difference in nonhematological toxicity, 
this was not significant, and small numbers preclude firm conclu-
sions from these analyses.
Discussion
This phase 3 trial utilized two mechanistically distinct single-
agent chemotherapeutics in unselected advanced TNBC and in 
biomarker-defined subpopulations that were specified a priori and 
were thought likely to have targetable defects in HR DNA repair. 
In the unselected subjects with TNBC, no evidence of a superior 
response to carboplatin was observed when compared with a stan-
dard of care taxane, docetaxel. Carboplatin was better tolerated 
than docetaxel when delivered at the full licensed dose. This trial 
demonstrates clinically important  activity for both agents. The 
level of response seen for docetaxel in this trial is consistent with 
that seen previously in breast cancer27, and the level of response 
for carboplatin was comparable to that seen in uncontrolled trials 
of single-agent platinums28,29 or combinations of carboplatin with 
gemcitabine in unselected TNBC30. The only other randomized trial 
that was conducted synchronously with our trial and was designed 
to specifically investigate platinum therapy in comparison with a 
standard of care in advanced TNBC included the substitution of the 
platinum therapy cisplatin for paclitaxel that was administered in a 
doublet with gemcitabine. In this study, treatment was continued 
until disease progression, as is common practice with paclitaxel, and 
the cisplatin doublet showed modestly increased activity compared 
to the paclitaxel doublet standard of care therapy31. A criticism of 
our study could be that subjects did not receive treatment to pro-
gression but only for six cycles (and, at investigator discretion, to 
a maximum of eight cycles). This was consistent with UK practice 
with docetaxel at the full licensed 100 mg/m2 dose, as this dose is 
rarely tolerated for more than six to eight cycles. This limited dura-
tion may explain the shorter PFS in our study compared to that in 
Hu et al.31 despite similar OS between studies and may have caused 
us to underestimate the effect of carboplatin in those without a pro-
gression event during treatment and who might have continued 
event-free for longer had treatment continued.
In contrast to the unselected population, the prespecified analy-
ses of treatment effect in subgroups found evidence of clinically and 
statistically significant biomarker–treatment interactions. There is a 
strong association between BRCA1 mutation and basal-like cancer32, 
and sporadic basal-like breast cancer subtypes show high degrees of 
chromosomal genomic instability3. We hypothesized that if, as has 
been widely speculated, there was a shared, profound BRCAness 
phenotype, sporadic basal-like cancers might have very high plati-
num sensitivity. We found no evidence that basal-like biomark-
ers predicted higher response to platinum than to docetaxel, with 
the drugs showing similar activity. A significant interaction was 
detected between treatment and the Prosigna–PAM50-identified 
subtypes that was driven by significantly increased response to 
docetaxel relative to poor platinum response in nonbasal forms of 
TNBC. This suggests an absence of targetable BRCAness in non-
basal TNBC and provides no evidence to change the standard of 
a
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Fig. 4 | Response rates in groups stratified according to HRD status. 
a,b, Absolute differences in the percentage of subjects who responded 
to treatment between treatment groups within subgroups stratified by 
dichotomized HRD score (a) and HR deficiency status (b). P values for the 
differences were calculated using a two-sided Fisher’s exact test. P values 
for interaction tests are based on a logistic regression model of response, 
with terms for biomarker status, treatment group and interaction. The 
number of subjects who responded to treatment out of all subjects in the 
group is shown on each bar. Axes scales show the percentage of subjects 
with a response.
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Fig. 5 | Response rates in groups stratified according to basal-like status. 
a,b, Absolute differences in the percentage of subjects who responded 
to treatment between treatment groups within subgroups stratified by 
basal-like status as defined by PAM50 signatures (a) and core basal 
status as determined by IHC analysis (b). P values for the differences were 
calculated using a two-sided Fisher’s exact test. P values for interactions 
were based on a logistic regression model of response, with terms for 
biomarker status, treatment group and interaction. 5NP, tumors that 
were negative for expression of ER, PgR, HER2, EGFR and Ck5/6 and were 
nonbasal by IHC. The number of subjects who responded to treatment 
out of all subjects in the group is shown on each bar. Axes scales show the 
percentage of subjects with a response.
care from a taxane to a platinum, which our data suggest is inferior 
in these subtypes. In contrast, platinum is a reasonable option in 
individuals with basal-like TNBC, particularly in those who fail to 
tolerate or have previously received a taxane. As the response rate 
in these cancers is much lower than that of breast cancer associated 
with a BRCA1/2 mutation, if there is a profound BRCAness pheno-
type that remains prevalent in metastatic basal-like breast cancer 
beyond the context of BRCA1 or BRCA2 mutation, it appears to lie 
within a subpopulation of this subtype that is yet to be identified.
BRCA1/2 mutation is a clinically validated and widely available 
biomarker that has predicted both a greater response and longer 
PFS in subjects treated with carboplatin than in those treated with 
docetaxel, demonstrating clinical utility for treatment selection in 
this setting. There was no evidence that BRCA1/2 mutation was 
associated with reduced activity of docetaxel compared to the wild 
type; docetaxel remains a valid and active, but inferior, treatment 
option in this setting. We did not find evidence of an OS advantage 
conferred by carboplatin therapy in carriers of a BRCA1/2 muta-
tion, but interpretation is confounded by the crossover design, 
as 56% of these subjects received carboplatin at progression. The 
high levels of response seen for carboplatin were similar to those 
reported for the combination of carboplatin and paclitaxel in an 
essentially similar population in the reference comparator arm in 
the phase II BROCADE trial33, supporting the notion that carbo-
platin monotherapy is highly active in this subject group. We found 
approximately one-third of subjects with a BRCA1/2 mutation did 
not respond to platinum therapy. Potential mechanisms underly-
ing resistance will be further explored in integrated whole-genome 
and whole-transcriptome sequencing analyses in primary tumor 
material, but the lack of extensive metastatic tumor samples from 
subjects immediately before platinum treatment will limit both the 
sensitivity of the analyses and the ability to draw firm conclusions.
In parallel, we tested the hypothesis that epigenetic silencing 
of BRCA1 through DNA methylation would show a similar treat-
ment interaction. Despite a similar number of subjects in genetic 
and epigenetic BRCAness subgroups, subjects with BRCA1 meth-
ylation or mRNA-low tumors had a higher response to docetaxel 
than to carboplatin. Exploratory analyses with the aim of optimiz-
ing cut-points for these biomarkers and analyses of these epigen-
etic biomarkers as continuous variables failed to find any signal of 
potential carboplatin treatment interaction. In stark contrast to 
the interaction between BRCA1/2 mutation and carboplatin treat-
ment effect, no evidence was found that supported a similar impact 
of epigenetic BRCAness; there was no interaction found between 
either BRCA1 methylation or BRCA1 mRNA-low status and car-
boplatin treatment effect. This suggests that genetic and epigenetic 
changes at the BRCA1 locus have important differences, at least in 
the context of predicting therapy response in metastatic breast can-
cer exposed to prior adjuvant chemotherapy. These results are con-
sistent with previous results from the nonrandomized TBCRC 009 
trial in metastatic TNBC28, in which the few tumors with BRCA1 
methylation showed no response to platinum therapy despite evi-
dence of chromosomal instability signatures. The majority of 
subjects in our study had received adjuvant chemotherapies that 
cause DNA lesions that engage HR in their repair. We measured 
BRCA1 methylation and mRNA level in archived primary tumor 
specimens, whereas treatment effect was assessed in metastases. We 
speculate that a higher proportion of BRCA1/2-mutation carriers 
retain an HR defect in metastatic disease than those with BRCA1 
methylated tumors (Supplementary Fig. 9). We suggest that muta-
tion creates a more resilient ‘hard’ BRCAness, whereas epigenetic 
BRCAness associated with BRCA1 methylation is more ‘soft’ and 
plastic20. The methylation of BRCA1 may be both more heteroge-
neous and/or more revertible in subclinical metastases that, when 
subjected to selection pressure by DNA-damaging adjuvant ther-
apy, lose their HR defect and survive, subsequently developing as 
HR-proficient clinical metastases that are not selectively platinum-
sensitive. Our hypothesis is supported by data from both preclinical 
patient-derived xenografts and primary breast tumors exposed to 
neoadjuvant chemotherapy34. In ovarian cancers, BRCA1 mutation, 
but not methylation, is associated with improved prognosis after 
platinum therapy35,36, and examination of biopsy pairs obtained pre- 
and postplatinum treatment shows reversion of BRCA1 methylation 
in 31% of tumors, with continued presence of methylation being 
associated with a PARP inhibitor response37. Although defects in 
HR are known to be revertible, mutational signatures would not 
be expected to disappear, as they are a permanent ‘scar’ of prior, 
even if no longer active, HR defects. Although our finding that the 
Myriad HRD assay did not specifically predict response to platinum 
as opposed to docetaxel in the setting of advanced TNBC disease 
contrasts to the reported association of a high Myriad HRD score 
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Fig. 6 | PFS for groups stratified according to basal-like status. a,b, PFS 
for treatment groups with subjects stratified according to basal-like status 
as defined by PAM50 (a) and core basal status as determined using IHC 
analysis (b). A negative value indicates a better response to docetaxel, and 
a positive value indicates a better response to carboplatin. The difference 
between restricted means with 95% CIs for stratified groups are shown  
on the figures. P values were calculated using a two-sided Student’s  
t-test comparing the restricted mean survival between treatments within 
biomarker groups. n at risk (events) shows the number of patients who 
remain in the analysis set at a given time point and the number of PFS 
events reported between time points.
with platinum response in the neoadjuvant setting in TNBC26, these 
neoadjuvant studies do not have a comparator arm to allow testing 
for interaction between biomarker status and any specific treatment 
effect of platinum chemotherapy as opposed to a relatively greater 
general chemotherapy responsiveness in HRD-high tumors than in 
HRD-low tumors. Where this specific effect of platinum therapy was 
examined in the randomized neoadjuvant context, the Myriad HRD 
assay did not show specific predictive performance for platinum 
response in unplanned retrospective analyses with limited power38. 
Metastatic disease exposed to prior adjuvant therapy is also a very 
different biological context than therapy in a treatment-naive neo-
adjuvant or adjuvant context. We hypothesize that adjuvant or neo-
adjuvant therapy drives reversal of the BRCA1-methylation-driven 
soft BRCAness34 HR defect, which we show, like BRCA1 mutation, 
produces a high HRD score in the primary tumor (Supplementary 
Fig. 4). This high score erodes the positive predictive value of the 
HRD score for therapy response in metastases, whereas a low 
HRD score will likely retain negative predictive value by excluding 
many tumors that have never had an HR defect, whether soft or 
hard. Since our analysis, a new HR deficiency mutational signature 
whole-genome sequence analysis methodology called ‘HRDetect’ 
has been described, with preliminary evidence of potential applica-
tion to formalin-fixed paraffin-embedded (FFPE) clinical materi-
als8. As HRDetect is also a cumulative historical measure of lifetime 
HR deficiency, the positive predictive value of this method may 
also be eroded by the effects of reversal of epigenetic HR defects 
in treatment-exposed metastatic disease and may require integra-
tion with additional biomarkers revealing a tumor’s current HR 
status. Analyses using HRDetect and multiple additional muta-
tional signatures and their integration with transcriptional signa-
tures of BRCAness and treatment response8,23,26,39,40 are planned but 
require whole-genome sequencing currently being piloted in TNT 
Trial FFPE material. These future analyses are beyond the scope of 
this manuscript.
Previous randomized studies have not examined treatment effect 
in a priori–defined subpopulations within advanced TNBC31. TNT 
highlights the heterogeneity in TNBC and the need to investigate 
therapeutic effects with planned analyses of biological subgroups. 
We provide the first evidence of the clinical utility of BRCA1/2 
genotyping to inform therapy choice in metastatic familial breast 
cancer and TNBC. In early TNBC, three recent trials have tested the 
role of the addition of platinum to anthracycline- and taxane-based 
neoadjuvant schedules and found evidence of increased pathologi-
cal tumor response41–43. These studies are underpowered for survival 
endpoints, but where reported, significant effects on disease-free 
survival were only seen when the alkylating agent cyclophospha-
mide was omitted from the control arm41. A nonsignificant trend 
was noted when a standard cyclophosphamide ‘backbone’ control 
was used in the CALGB 40603 study42. The dose-intense carbo-
platin regimen used in GeparSixto was recently compared with a 
sequential anthracycline and taxanes regimen and a high-dose 
cyclophosphamide-containing regimen, with no differences found 
in the primary pathological response measures44. It would seem that 
the use of alkylating agents in early TNBC is important, especially 
for individuals who have higher-stage disease with associated risk of 
recurrence and require a maximally effective therapy, to reduce this 
risk and achieve optimal surgery. The balance of additional toxicity 
and paucity of appropriately powered survival analyses testing inter-
action with potential predictive biomarkers for platinum response 
suggest the need for further studies before platinums are used rou-
tinely across all stages and biological subtypes of early TNBC. Data 
from our trial, although conducted in advanced TNBC, inform this 
landscape and raise important hypotheses for further testing in the 
setting of early breast cancer.
Many countries now perform inexpensive local BRCA1/2 germ-
line testing. Our results support BRCA1/2 germline testing to 
select patients for platinum chemotherapy for advanced disease. 
The OlympiAD trial45 recently reported a comparison between the 
potent PARP inhibitor olaparib, known to trap PARP1 on DNA, and 
the physician choice of nonplatinum standard of care chemothera-
pies in anthracycline- and taxane-exposed advanced gBRCA-BC. 
Other trials of potent PARP inhibitors are ongoing46. The PARP 
inhibitor olaparib is now approved in advanced gBRCA-BC, but 
this treatment may remain unaffordable to many health care sys-
tems and patients for many years. It remains unknown how potent 
PARP1-trapping inhibitors would compare with platinums in this 
setting, but the TNT Trial provides evidence that a widely available, 
affordable off-patent biomarker, which is enriched in the TNBCs 
prevalent in many developing countries47, has utility in selecting a 
population that could benefit during this period from the biologi-
cally targeted use of a highly active and inexpensive platinum che-
motherapy agent rather than the current licensed standard-of-care 
chemotherapies for breast cancer.
Methods
Methods, including statements of data availability and any asso-
ciated accession codes and references, are available at https://doi.
org/10.1038/s41591-018-0009-7.
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Methods
Study design. Conducted in 74 hospitals throughout the United Kingdom, TNT 
(NCT00532727) was a phase 3, parallel group, open-label randomized controlled 
trial with preplanned biomarker subgroup analyses. The trial was cosponsored by 
The Institute of Cancer Research and King's College London. It was approved by 
the East London and The City Main Research Ethics Committee. Trial sponsorship, 
governance, randomization procedures and balancing factors are described in 
the Supplementary Note.
Subjects. Eligible patients had to be considered fit to receive either study drug 
(carboplatin or docetaxel) and had to have measurable, confirmed advanced breast 
cancer unsuitable for local therapy that was histologically confirmed as ER-, PgR- 
and HER2-negative primary invasive breast cancer that either had an Allred/quick 
score of < 3 or a histo score (H-score) of < 10 or that were locally determined to be 
ER- and PgR-negative if other cut-offs were used (for example, 1%, 5% or 10%). 
The HER2-negative phenotype was defined as an IHC score of 0 or 1 + for HER2 
or a fluorescence in situ hybridization (FISH) or chromogenic in situ hybridization 
(CISH) score of 2 + and no amplification for the HER2 gene. An included subject 
could be ER- and HER2-negative, PgR-negative/unknown or any ER, PgR and 
HER2 status if the subject was known to have a BRCA1 or BRCA2 germline 
mutation and was otherwise eligible to participate (full eligibility criteria are listed 
in the Supplementary Note). Although subjects with TNBC who were hypothesized 
to have BRCAness phenotypes were the primary interest, subjects with unselected 
TNBC as well as those with BRCA1 or BRCA2 germline mutations were recruited 
to allow interaction testing of biomarker-positive and biomarker-negative 
populations in relation to response to each of these mechanistically distinct agents. 
Subjects provided written informed consent.
Procedures. Subjects were allocated (in a 1:1 ratio) to groups that received six 
cycles of carboplatin (area under the curve (AUC) 6), day 1 of a 3-weekly cycle, or 
six cycles of docetaxel (100 mg/m2), day 1 of a 3-weekly cycle (see Supplementary 
Note for details of allocation procedures, including the minimization-balancing 
factors used). For subjects responding to and tolerating treatment well, a further 
two cycles of treatment could be given, subject to local policy. Further details  
of chemotherapy and supportive medicines are described in the Supplementary 
Note. Subjects were offered six cycles of the alternative (crossover) treatment  
upon progression or where allocated treatment was discontinued due to  
toxicity (preprogression crossover). Subsequent management was at discretion  
of the clinician.
Tumor assessment through computed tomography (CT) scan was performed 
after three and six cycles (or at treatment discontinuation if earlier) and  once 
every 3 months thereafter until disease progression. Response was assessed as best 
response according to response evaluation criteria in solid tumors (RECIST).
Sample analyses. For consenting patients, one blood sample and archival 
primary invasive carcinoma, lymph node and any recurrent tumor specimens or 
a research biopsy from a metastatic site were collected. There was no requirement 
for a recurrent specimen to be provided. DNA was extracted using standard 
methodology. Central review of ER, PgR and HER status was performed at King’s 
College London (further details in Supplementary Note).
The Institute of Cancer Research is where germline BRCA1 and BRCA2 
mutation analysis was conducted and where status for subgroup analysis was 
centrally determined. Genomic DNA from white blood cell preparations was 
analyzed for intragenic mutations in BRCA1 and BRCA2 and for exon deletions 
and duplications throughout the coding sequence, and intron–exon boundaries 
was completed in all cases. This was either performed using Sanger sequencing 
together with multiplex ligation-dependent probe amplification (MLPA) or via 
next-generation sequencing using the Illumina TruSight Cancer Panel version 1.  
All intragenic mutations were confirmed through separate bidirectional Sanger 
sequencing. All exon deletions or duplications were confirmed through MLPA. 
The mutation nomenclature was in accordance with clinical convention, with 
numbering starting at the first A of the ATG initiation site, using BRCA1 
LRG_292_t1 and BRCA2 LRG_293_t1.
The DNA methylation status of the regulatory region of BRCA1 was 
determined using bisulfite sequencing and BRCA1 mRNA expression level from 
total RNA sequencing data from archival primary carcinoma (Supplementary Note, 
Supplementary Fig. 3 and Supplementary Table 5).
The Myriad HRD test includes three DNA-based measures of homologous 
recombination deficiency: whole-genome tumor loss of heterozygosity profiles 
(LOH), telomeric allelic imbalance (TAI) and large-scale state transitions (LST)22–24. 
All three scores are highly correlated with defects in BRCA1/2 and predict response 
to platinum-containing neoadjuvant chemotherapy in subjects with TNBC in trials 
without standard of care control arms26. The HRD score is calculated as the sum 
of the three individual scores, and a previously validated threshold of 42 was used 
in these analyses26. As part of the HRD assay, the sequencing data were used to call 
BRCA1/2 mutations, either germline or somatic, in the tumor. The Supplementary 
Note includes a description of HRD assay on TNT Trial samples.
Primary cancers were classified into basal-like subtypes using several classifiers, 
including an IHC panel7 and Prosigna48 (further details in Supplementary Note). 
Integration of transcriptional and whole-genome chromosomal instability, 
rearrangement and mutational signatures that have been associated with BRCA1 
or BRCA2 mutation and BRCA1 methylation and may specifically interact 
with carboplatin response8,22–26,39,40 were prespecified in the protocols as a priori 
subgroups analyses, but these integrated analyses are incompete and will be 
reported elsewhere.
Outcomes. The primary endpoint was ORR (complete or partial). The version of 
RECIST used for tumor assessment was documented and, where possible, cases 
assessed using RECIST version 1.0 were subsequently reassessed locally according 
to RECIST version 1.1. At study completion, an independent Response Evaluation 
Committee reviewed reported responses centrally (local assessment was used for 
primary analysis).
Secondary endpoints included PFS, OS, response to crossover treatment (as per 
primary endpoint), tolerability and safety.
Adverse events were assessed throughout treatment, graded according to 
National Cancer Institute Common Toxicity Criteria (version 3.0) and coded 
according to the Medical Dictionary for Regulatory Activities (MedDRA version 
14.0) with central clinical review (by the Chief Investigator) at study completion.
Statistical analyses. Evidence to inform sample size calculations was scarce; 
however, the ECOG 2100 trial49 suggested a 20–30% response rate for single-
agent taxane. TNT was designed on the premise of demonstrating superiority of 
carboplatin, with a 15% improvement in response rates designated as clinically 
important. Assuming 90% power and type I error α = 0.05 (two-sided), a sample 
size of at least 370 patients was required. The protocol recognized a priori that 
equivalence of response, accompanied by reduced toxicity with carboplatin, would 
also impact clinical practice.
Response rates were compared using two-sided Fisher's exact tests and logistic 
regression (see Supplementary Note for details regarding analysis of subgroups). 
Survival endpoints were displayed using Kaplan–Meier plots, and for survival 
analysis modeling, we utilized restricted mean survival methodology50 considering 
that the proportional hazards assumption required for Cox survival analysis did 
not hold.
Principal efficacy endpoints were analyzed according to the ITT population, 
including all 376 subjects randomized, and according to pre-planned biomarker 
subgroups (Supplementary Table 1); additional analysis groups and associated 
analysis methods are detailed in the Supplementary Note. Analyses are based on a 
database snapshot taken on 7 March 2016 and performed using STATA 13.
Reporting Summary. Further information on experimental design is available in 
the Nature Research Reporting Summary.
Data availability. Gene expression profiling data for the 50 genes used for Prosigna 
algorithm are available at: https://doi.org/10.5281/zenodo.1172633.
Other dichotomized biological data used for subgroup analyses are available in 
Supplementary Dataset 1.
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